Featured Research

from universities, journals, and other organizations

Improved Continence With Periurethral Suspension Technique Results After Robot-assisted Laparoscopic Radical Prostatectomy

Date:
September 3, 2009
Source:
European Association of Urology
Summary:
New research by urologists shows that the periurethral suspension technique results in significantly greater continence rates at three months after robot-assisted laparoscopic radical prostatectomy.

The September issue of European Urology, the official journal of the European Association of Urology, features an article and a video in the Surgery in Motion section by Vipul R. Patel et al, showing that the periurethral suspension technique results in significantly greater continence rates at 3 months after robot-assisted laparoscopic radical prostatectomy (RALP).

RALP is a widespread and rapidly expanding procedure around the world. Several studies have shown that RALP is feasible with limited blood loss, favourable complication rates, and short hospital times. Also, the continence rates 1 year after RALP reach over 90% in most of the large, single-centre prospective studies - results at least comparable to the open radical retropubic prostatectomy (RRP). However, early urinary incontinence following radical prostatectomy (RP) is still a significant concern for patients with prostate-confined cancer. A variety of surgical techniques have been used in an attempt to improve the early return of continence after RP.

"We describe our technique of periurethral retropubic suspension stitch during RALP and report its impact on early recovery of urinary continence in the European Urology article entitled 'Periurethral Suspension Stitch During Robot-Assisted Laparoscopic Radical Prostatectomy: Description of the Technique and Continence Outcomes'," says Dr Patel. "We analyse 331 consecutive patients who underwent RALP, 94 without the placement of suspension stitch (group 1) and 237 with the application of the suspension stitch (group 2)."

The suspension technique resulted in significantly greater continence rates at 3 months after RALP. The median/mean interval to recovery of continence was also statistically significantly shorter in the suspension group. Continence was defined as the use of no absorbent pads or no leakage of urine.


Story Source:

The above story is based on materials provided by European Association of Urology. Note: Materials may be edited for content and length.


Journal Reference:

  1. Vipul R. Patel, Rafael F. Coelho, Kenneth J. Palmer, Bernardo Rocco. Periurethral Suspension Stitch During Robot-Assisted Laparoscopic Radical Prostatectomy: Description of the Technique and Continence Outcomes. European Urology, 2009; 56 (3): 472 DOI: 10.1016/j.eururo.2009.06.007

Cite This Page:

European Association of Urology. "Improved Continence With Periurethral Suspension Technique Results After Robot-assisted Laparoscopic Radical Prostatectomy." ScienceDaily. ScienceDaily, 3 September 2009. <www.sciencedaily.com/releases/2009/09/090903163900.htm>.
European Association of Urology. (2009, September 3). Improved Continence With Periurethral Suspension Technique Results After Robot-assisted Laparoscopic Radical Prostatectomy. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2009/09/090903163900.htm
European Association of Urology. "Improved Continence With Periurethral Suspension Technique Results After Robot-assisted Laparoscopic Radical Prostatectomy." ScienceDaily. www.sciencedaily.com/releases/2009/09/090903163900.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com
$23.6 Billion Awarded To Widow In Smoking Lawsuit

$23.6 Billion Awarded To Widow In Smoking Lawsuit

Newsy (July 20, 2014) Cynthia Robinson claims R.J. Reynolds Tobacco Company hid the health and addiction risks of its products, leading to the death of her husband in 1996. Video provided by Newsy
Powered by NewsLook.com
Tooth Plaque Provides Insight Into Diets Of Ancient People

Tooth Plaque Provides Insight Into Diets Of Ancient People

Newsy (July 19, 2014) Research on plaque from ancient teeth shows that our prehistoric ancestor's had a detailed understanding of plants long before developing agriculture. Video provided by Newsy
Powered by NewsLook.com
Contaminated Water Kills 3 Babies in South African Town

Contaminated Water Kills 3 Babies in South African Town

AFP (July 18, 2014) Contaminated water in South Africa's northwestern town of Bloemhof kills three babies and hospitalises over 500 people. The incident highlights growing fears over water safety in South Africa. Duration: 02:22 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins